This retrospective study assessed the effectiveness of eltrombopag (EPAG), a thrombopoietin receptor agonist, in the treatment of poor graft function (PGF) following an allogeneic haemopoietic stem cell transplantation (HSCT). Complete response was defined as normalization of blood counts, whereas partial response was defined as transfusion independence. A total of 48 patients with full donor chimerism after HSCT, received EPAG for a median of 120 days (range 10–591). Patients with uni- bi- or tri-lineage cytopenia started treatment at a median of 95 days (range 17–877) after HSCT. The overall response rate was 75%: 24 patients had a complete response and 12 had a partial response. Positive predictors of response were an HLA-matched donor, a CD34+ dose at transplant > 4 × 106/kg, and starting EPAG treatment at least 90 days after HSCT. Patients with more than one positive predictor had a response rate of 92% for the overall patient cohort and 94% for patients with tri-lineage cytopenia. One-year survival was 89% for complete responders, 60% for partial responders and 20% for non-responders (p = 0.0004). EPAG improves peripheral blood counts in patients with poor graft function following HSCT. Response to EPAG can be predicted and has a significant impact on survival.

Giammarco, S., Sica, S., Chiusolo, P., Laurenti, L., Sora, F., Martino, M., Metafuni, E., Busca, A., Risitano, A., Vallejo, C., Bacigalupo, A., Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study, <<INTERNATIONAL JOURNAL OF HEMATOLOGY>>, 2021; 114 (2): 228-234. [doi:10.1007/s12185-021-03153-3] [http://hdl.handle.net/10807/184833]

Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study

Sica, S.;Chiusolo, P.;Laurenti, L.;Sora, F.;Martino, M.;Metafuni, E.;Bacigalupo, A.
2021

Abstract

This retrospective study assessed the effectiveness of eltrombopag (EPAG), a thrombopoietin receptor agonist, in the treatment of poor graft function (PGF) following an allogeneic haemopoietic stem cell transplantation (HSCT). Complete response was defined as normalization of blood counts, whereas partial response was defined as transfusion independence. A total of 48 patients with full donor chimerism after HSCT, received EPAG for a median of 120 days (range 10–591). Patients with uni- bi- or tri-lineage cytopenia started treatment at a median of 95 days (range 17–877) after HSCT. The overall response rate was 75%: 24 patients had a complete response and 12 had a partial response. Positive predictors of response were an HLA-matched donor, a CD34+ dose at transplant > 4 × 106/kg, and starting EPAG treatment at least 90 days after HSCT. Patients with more than one positive predictor had a response rate of 92% for the overall patient cohort and 94% for patients with tri-lineage cytopenia. One-year survival was 89% for complete responders, 60% for partial responders and 20% for non-responders (p = 0.0004). EPAG improves peripheral blood counts in patients with poor graft function following HSCT. Response to EPAG can be predicted and has a significant impact on survival.
Inglese
Giammarco, S., Sica, S., Chiusolo, P., Laurenti, L., Sora, F., Martino, M., Metafuni, E., Busca, A., Risitano, A., Vallejo, C., Bacigalupo, A., Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study, <<INTERNATIONAL JOURNAL OF HEMATOLOGY>>, 2021; 114 (2): 228-234. [doi:10.1007/s12185-021-03153-3] [http://hdl.handle.net/10807/184833]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/184833
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact